Formuepleje A/S’s Vertex Pharmaceuticals VRTX Stock Holding History

Formuepleje A/S’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$696K	Sell	1,332 -1,077	-45%	-$551K	0.06%	95
2026 Q2	$1.2M	Buy	+2,409	New	+$1.07M	0.09%	78
2023 Q4	–	Sell	-46,326	Closed	-$16.1M	–	94
2023 Q3	$16.1M	Sell	46,326 -1,102	-2%	-$385K	1.49%	20
2023 Q2	$16.7M	Sell	47,428 -34,421	-42%	-$11.6M	1.46%	21
2023 Q1	$25.8M	Buy	81,849 +10,137	+14%	+$3.04M	1.89%	19
2022 Q4	$20.7M	Buy	71,712 +31,833	+80%	+$9.7M	1.75%	18
2022 Q3	$11.5M	Buy	39,879 +25,329	+174%	+$7.29M	0.94%	38
2022 Q2	$4.1M	Sell	14,550 -3,884	-21%	-$1.04M	0.25%	54
2022 Q1	$4.73M	Sell	18,434 -4,955	-21%	-$1.18M	0.21%	56
2021 Q4	$5.14M	Sell	23,389 -3,953	-14%	-$769K	0.2%	59
2021 Q3	$4.96M	Buy	27,342 +16,144	+144%	+$3.15M	0.2%	56
2021 Q2	$2.26M	Buy	+11,198	New	+$2.34M	0.09%	62

Other funds holding VRTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Formuepleje A/S's VRTX Position: Q3 2026 in Review

Formuepleje A/S reduced its Vertex Pharmaceuticals (VRTX) stake by 45% in Q3 2026, selling an estimated $551K and leaving 1,332 shares worth $696K. The position accounts for 0.06% of the portfolio, ranked #95.

Formuepleje A/S first reported a position in VRTX in Q2 2021 and has held it in 12 quarters since. The position peaked at $25.8M in Q1 2023. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Formuepleje A/S held 1,332 shares of Vertex Pharmaceuticals worth $696K as of Q3 2026.
Formuepleje A/S sold 1,077 Vertex Pharmaceuticals shares in Q3 2026, an estimated $551K.
Vertex Pharmaceuticals made up 0.06% of Formuepleje A/S's portfolio in Q3 2026, its #95 holding.
Formuepleje A/S first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 12 quarters since.
Formuepleje A/S's Vertex Pharmaceuticals position peaked at $25.8M in Q1 2023.
1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Formuepleje A/S's 13F filing for Q3 2026, filed 15 Oct 2026.